{"name":"Scholar Rock","slug":"scholar-rock","ticker":"SRRK","exchange":"NASDAQ","domain":"scholarrock.com","description":"Scholar Rock is a biopharmaceutical company focused on developing treatments for neuromuscular and rare diseases. The company's lead product candidate, apitegromab, is being developed for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Scholar Rock has a strong pipeline of product candidates in various stages of development.","hq":"Cambridge, MA","founded":0,"employees":"","ceo":"Jay Bhatt","sector":"Neuromuscular / Rare Disease","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$580M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":208440000,"netIncome":-377939000,"cash":323527000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2018"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"apitegromab patent cliff ($0.0B at risk)","drug":"apitegromab","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"SRK-181","genericName":"SRK-181","slug":"srk-181","indication":"Other","status":"phase_1"},{"name":"SRK-015","genericName":"SRK-015","slug":"srk-015","indication":"Other","status":"phase_2"},{"name":"SRK-439","genericName":"SRK-439","slug":"srk-439","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"SRK-181","genericName":"SRK-181","slug":"srk-181","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"SRK-015","genericName":"SRK-015","slug":"srk-015","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"SRK-439","genericName":"SRK-439","slug":"srk-439","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Scholar Rock Announces FDA Fast Track Designation for Apitegromab","summary":"The FDA granted Fast Track designation to apitegromab for the treatment of FSHD.","drugName":"apitegromab","sentiment":"positive"},{"date":"2023-11-07","type":"earnings","headline":"Scholar Rock Reports Third Quarter 2023 Financial Results","summary":"The company reported a net loss of $43.1 million for the third quarter of 2023.","drugName":"","sentiment":"neutral"},{"date":"2023-08-28","type":"deal","headline":"Scholar Rock Announces Collaboration with Pfizer to Develop Apitegromab","summary":"The company entered into a collaboration with Pfizer to develop apitegromab for the treatment of FSHD.","drugName":"apitegromab","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-07","type":"regulatory","source":"simplywall.st","summary":"A Look At Scholar Rock (SRRK) Valuation After Apitegromab BLA Resubmission And Reduced Regulatory Risk - simplywall.st","headline":"A Look At Scholar Rock (SRRK) Valuation After Apitegromab BLA Resubmission And Reduced Regulatory Risk","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxOM2JzMUsyRDJ1UHZubDVKVlVTRTI0amtqejdRLTdvLWRnYnM1MDFyWmVqR3ZrMnhxbnJoWGNLaHg2YklYZzR3aUpRTWh4SlJSUXM1QnRaNjdGLTFZYkhOaHl3eUkzaTgtNkhaVXdrZEFSWTdabFlwbmlYdVFMTzNYdlhsak9fNTU1NUx2Q2VjTHRmZUZBWjJLUWtmSUFQQ0hLNlI0RWVvRDZ1dW5oWjVqN3EtWHhkVm5aSkNCUDdUWFRNOGVBUVF2Mnc4dXRDU01YT2JoeWcySHNUV1JweGVjT0NuTExrNUgtakdwa1pQaFM3c3lvZmRPLWVEMEFMMDg?oc=5","date":"2026-03-21","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Are Bullish on These Healthcare Stocks: Viatris (VTRS), Scholar Rock Holding (SRRK) - The Globe and Mail","headline":"Analysts Are Bullish on These Healthcare Stocks: Viatris (VTRS), Scholar Rock Holding (SRRK)","sentiment":"neutral"},{"date":"2026-03-03","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNdTFGcEVpUU1JekZ4RUxwMHRKUmVlT1I3cDBiR3Jtc1BxT1VmTld6RlhtVUZDd1VFd0xiV0hLVi1pbzFNcnQzdC1ybmhELW5aUTJCbTBMcENyWUs2Sml1eGlwNzdNOVNMQy1RcTI1UUlvYVoyeERrRGx0LVlvV3hiMXZJY2hSZldTek9nWDRiY0Rvb3ZxRzFkRjY3SjJ1Wm8?oc=5","date":"2025-10-14","type":"pipeline","source":"The Pharma Letter","summary":"Scholar Rock shares suffer on manufacturing site woes - The Pharma Letter","headline":"Scholar Rock shares suffer on manufacturing site woes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPYWw5YVFuSE1Vak5PaEM2UDJFaGNEQ1pCQkt6SnIyWGdpWC1GMjIwRFpkN1VCMWRKNm9YMzBHQWRucjNzN3BmZUhka2lPNnphSnVqaVFsM21VZlg1ZV9uRGpaaDlHd1p1OWZWX2Y1dzBPQmQ4Y1NCNHQxcVRtUGluaEhFWE4xT2NPLVBfX3Frbw?oc=5","date":"2025-10-13","type":"pipeline","source":"The Motley Fool","summary":"Why Scholar Rock Stock Got Socked on Monday - The Motley Fool","headline":"Why Scholar Rock Stock Got Socked on Monday","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxNNGU4TEROVFBUcGs3WXRna1FlaVRjS2k2UnJrZkdHcXF4cHoybHd1YnhjM2ZIVDhSa0ZITVlJbXpEWkc2QlE1Tk44WnVOVHJZYS1ud2hYSlhraExwNDl4eS02czZrT05XMVhYNWNuVVNBZVJLREViSU1WOERwbUpHNnJzQ0RzVnBFSFlONDJ3YjJBaVJEMm5jdlRnYnBnVU5SbktjQy1EMDhiS1pCZFJKQk9Ja2lHZldmLXZuc1ZVTFY4U0FUcDFwVDRYcGFqMkxtM01GaEF6ZFo0a0dOUk5MZDRXNFZaUl9LelRwc3FQY0luZVU?oc=5","date":"2025-09-26","type":"pipeline","source":"Benzinga","summary":"Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday - Benzinga","headline":"Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxPd2RTZW5WNmxXcGZ5a05kM1p1bXFzNXJLMV8tb1ROVVF2S0NPUzcyY1h6OFlYd0xGaENFdklsZEk2OUpFdC0wajN2ZWVRNUhwT0l6anc0SnpaeHdIakp3bmZxWGhkT194TEZCal9zVU5qRHJXOE9YWUZwN3ctd1FEOElmX2xKdURrN0R1UXEyclA0ZWNOSWpEOU9nbDZfTW5oZXU2bXlic0Q1b1QyT3hGWmd1N2FFSGozREFwUXQySHFQR2NoT081Yk5R?oc=5","date":"2025-09-23","type":"regulatory","source":"Reuters","summary":"US FDA declines to approve Scholar Rock's muscle weakness drug; shares fall - Reuters","headline":"US FDA declines to approve Scholar Rock's muscle weakness drug; shares fall","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOcjFCclV0M0xNMTdlQ3lkMG5RSFVncWNJOWxaX2RvbnBLdU5lMDFmSV9iajI5U00yMHh0a1RRcjhqOHpSX3JjZTlRaHo3VW9tY29xQ0hPN2xFMHR4cjRGY3E4Xy1HWXRjdFZIRlc3a0kzX3FQMGYzVlc3WTdabS15WjJ4V3oxNzhfdlgtaWg5Z3FJdmV4XzAzQw?oc=5","date":"2025-09-23","type":"regulatory","source":"The Pharma Letter","summary":"FDA dishes out CRL for Scholar Rock’s apitegromab - The Pharma Letter","headline":"FDA dishes out CRL for Scholar Rock’s apitegromab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPUkNMWThnUGxOY1JZeTZ6dGZHbWMtUHMwWC1pYTgwdThOYzQ5ZFRvM2FyWmlfeHF6aG5XaGtiSWtINkpST0loZTVXOWNMTXhmeGtWRUlFSUNoMDdlUWE3dEhpMGZUcDVCMDVodUVvVGZScmwwcWlSODZZQ3lFVXdsQlBNcWpTWVlKYm5Bd3VkOE9UYXM4WlZtX1RlMkhRRmZzQ1d3NS1mdjZvcGhE?oc=5","date":"2025-09-23","type":"regulatory","source":"Fierce Pharma","summary":"FDA rejects Scholar Rock's SMA drug, citing issues at Novo's Catalent Indiana site - Fierce Pharma","headline":"FDA rejects Scholar Rock's SMA drug, citing issues at Novo's Catalent Indiana site","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNakJXQ2stVTRpVjNsMnVqcmtIbWhla0dMQ0ZiLVNjeGVPM0RQVUZ6anF2d1BDT1VWd0ZTVlI0Mk5SbHlqUUV3ZWNveGtkZmhxTE1wYmo2cXFxN3Z6MjRXNnZMdFFMcWkzeXEta3Rpd2p4TUZEMXZ1Y1IzSFhKMHZHcWo3bXkteDYtQ1FSQVR6YjVzLVlVY2VPLXJMV0ItR1U5TnRiTXhNVDVUdnp0b3JXSQ?oc=5","date":"2025-07-09","type":"pipeline","source":"tastylive","summary":"From GLP-1s to Myostatin: The Trade Behind Eli Lilly’s Quiet Obesity Power Play - tastylive","headline":"From GLP-1s to Myostatin: The Trade Behind Eli Lilly’s Quiet Obesity Power Play","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPOGZreHk4REVCQ1lKQWx5OXFOZXpzbkhvV2M0cWdWR3lOQTlib2M0WVdhYmU2alQ0OFl5M1ByR0dYNDNpVnRBcEZISDRKUjZ3eVFlT0hUR29NWnpxUTM3UUtJcGhlX2pkdU5jeXpHRXBWUGdrWVJGbGRkbjVFNVFwSkRuUzh3LVJWNHczV01QMEtNQzlITDVhSmZXM0lNOThRVjJHaGR0YTZxZWhMazlVcw?oc=5","date":"2025-06-18","type":"trial","source":"Investopedia","summary":"Scholar Rock Stock Soars on Biopharma Firm's Weight-Loss Drug Trial Results - Investopedia","headline":"Scholar Rock Stock Soars on Biopharma Firm's Weight-Loss Drug Trial Results","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPZlA5aWczS2NwR0kzSkVnRGFSaWYyUUF2NS16Uk83Z2hlSXhCd0ZTVTlMVERzekJpVng0eXllSkM1THJ5aTlTRzVUNlcxaHhiQzZDMV9sQ1podmRFU0dmeFE0WDg2R0I1WUZPZTljUko4dldOeG5xdXY3bXFZdnRyR1FNYTNoN05CZTVKeGhoRHhEeVpa?oc=5","date":"2025-06-18","type":"trial","source":"BioPharma Dive","summary":"Scholar Rock drug preserves muscle in obesity trial - BioPharma Dive","headline":"Scholar Rock drug preserves muscle in obesity trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxPeTlKeFlQNTdaT1MwVjYwc0FxNkhNdmpuRGFzWlN3OTJncEgzS1dsdG02V2hpQmxrcXBSZmFVU2UxeC1tX3o3U0k4VmhIQlNmTkFET1JyWHdRRkZnNzBoQmc5NWVSOXRzVGtfY2hKcUhlQURvSm4yRmllRHB4dkpJRml5MTVoLWNWLUZxQXJqeWZxYnFmdWVHajFhOEVmYUpDeXR2Wk0xWUszaHc2bmUteS1ReTJUZnBOLVh4WUxQMWlaNmZWNXRnMm40Qy1aOE43aG1VVUw0Z3llb3VYOG4tNFU1UQ?oc=5","date":"2025-06-13","type":"pipeline","source":"Stocktwits","summary":"Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased - Stocktwits","headline":"Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased","sentiment":"neutral"}],"patents":[{"drugName":"apitegromab","drugSlug":"apitegromab","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":3,"phaseCounts":{"phase_1":2,"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Pfizer","Biogen","Sarepta Therapeutics"],"therapeuticFocus":["Neuromuscular Diseases","Rare Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2018-12-31","revenueHistory":[{"value":0,"period":"2018-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":208440000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-377939000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":323527000,"cashHistory":[],"totalAssets":404272000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}